

**NEWS RELEASE  
FOR IMMEDIATE RELEASE**

**Company Contact:**  
Stan Fronczkowski  
Chief Financial Officer  
(302) 456-6789  
[www.sdix.com](http://www.sdix.com)

**Investor Contact:**  
Brian Korb  
The Trout Group  
(646) 378-2923  
[bkorb@troutgroup.com](mailto:bkorb@troutgroup.com)

**STRATEGIC DIAGNOSTICS INC. APPROVES STOCK REPURCHASE PROGRAM**

**NEWARK, Del., October 20, 2008 - Strategic Diagnostics Inc. (NASDAQ: SDIX)** - a leading provider of biotechnology-based detection solutions for a broad range of food, water, agricultural, industrial, environmental and scientific applications, today announced that its Board of Directors has approved a program to repurchase up to \$3.0 million of the Company's outstanding shares of common stock from time to time over the next 12 months, depending on market conditions, share price and other factors.

The repurchases may be made on the open market, in block trades or otherwise. The program may be suspended or discontinued at any time.

"We believe that our stock price does not reflect our belief in the long term value of Strategic Diagnostics. A repurchase program will benefit SDI's shareholders and demonstrates our Board's and management team's confidence in our business." said Francis M. DiNuzzo, the Company's President and Chief Executive Officer.

The stock repurchase program will be funded using the Company's working capital. The Company has cash, cash equivalents and marketable securities of approximately \$11 million and approximately 20.4 million shares of common stock outstanding.

**About Strategic Diagnostics Inc.**

Strategic Diagnostics Inc. is a leading provider of antibody technology to the Life Science marketplace. Additionally, the Company provides biotechnology-based detection solutions for a broad range of food, water, agricultural, and environmental applications. By applying its core competencies of antibody and assay development, the Company produces unique, sophisticated reagents, reagent systems, antibody design services and bio-detection solutions to customer needs. Customers benefit from the enablement of their research into critical health care challenges of disease understanding, therapeutic development and diagnostic discovery. Industrial customers benefit with quantifiable "return on investment" by reducing time, labor, and/or material costs. All this is accomplished while increasing accuracy, reliability and actionability of essential test results. The Company is focused on sustaining this competitive advantage by leveraging its expertise in antibody design, immunology, proteomics, bio-luminescence and other bio-reactive technologies to continue its successful customer-focused research and development efforts. Recent innovations in high throughput production of antibodies from genetic antigens will complement the Company's established leadership in commercial and custom antibody production for the Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position the Company for broader participation in proteomics research and discovery.

*This news release contains forward-looking statements reflecting SDI's current expectations. When used in this press release, the words "anticipate", "could", "enable", "estimate", "intend", "expect", "believe", "potential", "will", "should", "project" "plan" and similar expressions as they relate to SDI are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDI at this time. Such risks and uncertainties include, without limitation, changes in demand for products, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, the successful integration and consolidation of the Maine production facilities, inability to obtain or delays in obtaining fourth party, including AOAC, or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDI's public filings with the U.S. Securities and Exchange Commission.*